Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.
Not all reports are available for public preview. For more information, please contact us.
Focus of the Report: This report focuses on amniotic allograft (AA) for treatment or prevention of tendon and ligament injuries.
Technology Description: AA is prepared from sheets of amniotic membrane obtained shortly after caesarean delivery. For some products, amniotic membrane is de…
Berotralstat is an oral plasma kallikrein inhibitor for prevention of hereditary angioedema attacks.
Retevmo (selpercatinib) is a novel oral highly selective RET inhibitor indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).
Lisocabtagene maraleucel (liso-cel) is an investigational, autologous chimeric antigen receptor (CAR) T-cell therapy, a novel type of immunotherapy in which a patient’s own immune cells are genetically re-programmed to target and attack cancer cells. It is proposed to treat adults with relapsed or refractory large B-cell lymphoma after at least 2 prior therapies.
Focus of the Report: The use of minimally invasive sacroiliac joint (SIJ) fusion with the iFuse Implant System (SI-Bone Inc.) for the treatment of adults with SIJ dysfunction who have not experienced adequate relief from nonsurgical management (NSM).
Technology Description: The iFuse i…
Voclosporin is an oral, investigational calcineurin inhibitor (CNI) that is similar in structure to cyclosporine. It is proposed as an addition to standard induction therapy for the treatment of active lupus nephritis in adult patients.
Remestemcel-L is an allogeneic liquid cell suspension of ex-vivo cultured adult human mesenchymal stem cells derived from healthy donor bone marrow proposed for the treatment of pediatric patients with acute graft-versus-host-disease (aGVHD) refractory to standard first-line steroid therapy.
Focus of the Report: This report focuses on matrix-induced autologous chondrocyte implantation (MACI) for the treatment of patients with chondral defects of the knee.
Technology Description: MACI is a multi-stage procedure that involves 2 surgeries. During an initial arthroscopic surge…
Enspryng (satralizumab) is interleukin-6 (IL-6) receptor antagonist indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. It is administered by subcutaneous injection.
Focus of the Report: The use of deep brain stimulation (DBS) for treatment of refractory obsessive-compulsive disorder (OCD).
Technology Description: DBS therapy uses mild electrical impulses to regulate electrical activity of neural circuits. Patients undergo surgery to implant a med…